Unraveling Vascular Inflammation

  • Teague H
  • Ahlman M
  • Alavi A
  • et al.
Citations of this article
Mendeley users who have this article in their library.


Inflammation is a critical factor in early atherosclerosis and its progression to myocardial infarction. The search for valid surrogate markers of arterial vascular inflammation led to the increasing use of positron emission tomography/ computed tomography. Indeed, vascular inflammation is associated with future risk for myocardial infarction and can be modulated with short-term therapies, such as statins, that mitigate cardiovascular risk. However, to better understand vascular inflammation and its mechanisms, a panel was recently convened of world experts in immunology, human translational research, and positron emission tomographic vascular imaging. This contemporary review first strives to understand the diverse roles of immune cells implicated in atherogenesis. Next, the authors describe human chronic inflammatory disease models that can help elucidate the pathophysiology of vascular inflammation. Finally, the authors review positron emission tomography–based imaging techniques to characterize the vessel wall in vivo. (J Am Coll Cardiol 2017;70:1403–12) Published by Elsevier on behalf of the American College of Cardiology Foundation. Nestle is an employee of Sanofi. Dr. Gelfand has served as a consultant for Coherus (data and safety monitoring board), Dermira, Janssen Biologics, Merck (data and safety monitoring board), Novartis, Regeneron, Dr. Reddy's Laboratories, Sanofi, and Pfizer; has received honoraria and research grants (to the Trustees of the University of Pennsylvania) from Abbvie, Janssen, Novartis, Regeneron, Sanofi, Celgene, and Pfizer; has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Abbvie; and coholds a patent on resiquimod for the treatment of cutaneous T cell lymphoma. Dr. Grinspoon has served as a consultant for and received honoraria from Navidea Pharmaceuticals and Theratechnologies; and has received research grants (to the Massachusetts General Hospital) from Navidea Pharmaceuticals, KOWA Pharmaceuticals, Gilead Sciences, and Theratechnologies. Dr. Ridker has received investigator-initiated research support from the National Heart, Lung, and Blood Institute, Pfizer, AstraZenenca, Novartis, and Kowa; and is listed as a coinventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardio-vascular disease and diabetes that have been licensed to AstraZeneca and Siemens. Dr. Tawakol has served as a consultant for Actelion Pharmaceuticals; and has received research grants (to the Massachusetts General Hospital) from Actelion and Genentech. I S S N 0 7 3 5 -1 0 9 7 / $ 3 6 . 0 0 h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 7 . 0 7 . 7 5 0




Teague, H. L., Ahlman, M. A., Alavi, A., Wagner, D. D., Lichtman, A. H., Nahrendorf, M., … Mehta, N. N. (2017). Unraveling Vascular Inflammation. Journal of the American College of Cardiology, 70(11), 1403–1412. https://doi.org/10.1016/j.jacc.2017.07.750

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free